BIOVIA’s Post

Building causal #AI to discover new biology matters even more when you can do it with one software click. Introducing with pride TargetMATCH, Owkin’s #AI target discovery engine that uses multimodal patient data to identify multiscale biology for new drug targets, indications and patient subgroups that will benefit the most from treatments. TargetMATCH harnesses state-of-the-art AI technology like foundation models, LLMs and causal AI, to deliver breakthrough biology at any moment. This is pilar of our company and the pharma of tomorrow that we aim to replace. Big up to Eric Durand and Elodie Pronier teams as well as the amazing Alistair Jennings Davide Mantiero, PhD and Antonia Trower Rodrigo Barnes and Thea Backlar teams among others. Learn more at https://lnkd.in/ebxnvaha

No. 1 request from last month's Foundational Models webinar was to better understand which models are best suited for specific use cases. You asked, and we deliver! Join us for our upcoming webinar, “Mapping Foundational Models to Use Cases in Biotech and Pharma”, presented by our in-house AI experts, Daniel and Dror. Here is what they will cover: 🔹 Most promising foundational models for biotech and pharma today 🔹 How to categorize these models into various biologically compelling categories 🔹 Data and compute requirements for each application More details below 👇 https://lnkd.in/dYhPYiFW #bioinformatics #dataanalytics #biotech#computational

Reflecting back on #JPM24 to a panel with Life Science Luminaries Aviv Regev (Genentech), Scott Gottlieb & Amy Abernethy on #TechBio. While the panel was too short, the consensus was clear: while there will be ups and downs over the coming years as AI tools and technologies are deployed, the inevitable outcome by 2030 will be a transformation in the way medicines are discovered and developed. What problems in drug discovery and development do you think will most benefit from ML and AI tools in the short term? The long term?

It has been a long-long time since I have seen an “emerging” biotech company like Recursion capture the imagination of the biggest companies like my ex-firm Genentech. In fact, it was likely Genentech who had that same type of impact 30 plus years ago and that all lead to amazing innovations that benefited countless patients since. Bravo Recursion! Reflecting on highlights at #JPM24, Recursion CEO Chris Gibson announced LOWE, an LLM-Orchestrated workflow engine designed to perform complex drug discovery tasks using a natural language interface. Headquartered in Salt Lake City, they are a founding member of BioHive, the Utah life sciences industry collective I highlighted in a past post. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. They are uniting technology, biology and chemistry to advance the future of medicine. Exciting to see the transformation of drug discovery and development. Some additional companies making a splash in the Great Salt Lake: IONIQ Sciences, Inc., Jared Bauer, CEO, developed the IONIQ System that utilizes patented Electrical Impedance Analytics (EIA) or bioimpedance technology to non-invasively record approximately 10,000 electrical measurements of the body over a 20 minute period. Their proprietary algorithm processes this data near-instantaneously to determine the likelihood of malignancy in its earliest stages thereby potentially improving survival and reducing costs. Q Therapeutics, CEO Steve Borst, President, Chief Executive Officer, and Chairman of the Board of Directors, knows the restorative mechanism of Q-Cells® will be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, cerebral palsy and stroke. Q-Cells® are adult progenitor cells, restricted in their ability to differentiate only into glia, the unsung heroes of the brain.   #drugdiscovery #BioHive #machinelearning #AI #ML

NOW ON-DEMAND: Dr. Joseph Zabinski discusses the digital phenotyping process and several concrete applications to demonstrate how AI can add value to analyses of the patient journey across the life sciences spectrum. OM1, Inc. Watch it now: https://bit.ly/4488URS

Peer AI's Chief Scientific Officer Ravi Ramachandran is looking forward to connecting with pharma and biotech colleagues at the @MAPS Conference! If you want to explore how Peer AI can help, let’s connect! #MAPSPR24 #MedicalAffairs #RegulatoryMedicalWriting

🎉 We are so excited to be headed back to PMRC! 🎉 Dan is primed to host an insightful discussion around gen AI and barriers to success, while Katy and Leona will be at the booth with some FRESH research insights to share. There may even be a nice little reward for stopping by our booth... 😉 If you will be at PMRC, be sure to stop by and join the discussion! #healthcare #mrx #insights

Discover Tomorrow’s Drugs Today! Join our webinar today at 3:15 PM GMT (10:15 AM EST). Discover how bioXcelerate AI's PleioGraph suite uses advanced machine learning to decipher causal disease pathways across multi-omics data. 💡 In this 45-minute session, we'll introduce #SwitchStep and #ImpMap, two powerful components of PleioGraph that address key limitations in existing analytical methods. Register here to receive the link: https://lnkd.in/ebMne5hy #Webinar #bioXcelerateAI #DrugDiscovery #DrugDevelopment

"It's not trivial to make sure that you have your #data (management) right, to then be able to apply advanced analytics." Check out MC Services AG's highlight of our BD Director Amparo Cuéllar from Bio-EUROPE 👇 She discusses 🌿 The importance of ensuring that application of #AI and other advanced analytics is grounded in an understanding of #biology & your business strategy 📈 #dataanalytics trends in the life sciences 🦎 What's next for BioLizard 🚀 Advice for companies who want to become more #datadriven

Thanks Dataiku for the feature in your #AIandUs series!